WO2012088044A3 - Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity - Google Patents

Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity Download PDF

Info

Publication number
WO2012088044A3
WO2012088044A3 PCT/US2011/066036 US2011066036W WO2012088044A3 WO 2012088044 A3 WO2012088044 A3 WO 2012088044A3 US 2011066036 W US2011066036 W US 2011066036W WO 2012088044 A3 WO2012088044 A3 WO 2012088044A3
Authority
WO
WIPO (PCT)
Prior art keywords
ocular surface
compositions
methods
visual acuity
optical function
Prior art date
Application number
PCT/US2011/066036
Other languages
French (fr)
Other versions
WO2012088044A2 (en
Inventor
James Mcmillan
Original Assignee
James Mcmillan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James Mcmillan filed Critical James Mcmillan
Publication of WO2012088044A2 publication Critical patent/WO2012088044A2/en
Publication of WO2012088044A3 publication Critical patent/WO2012088044A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

In one aspect, the invention provides an ophthalmic composition comprising active Vitamin D and at least one topical steroid in a formulation suitable for topical administration to the eye. In some embodiments, the composition comprises an amount of active Vitamin D and at least one topical steroid in an amount effective to provide at least one of: relief of symptoms of dry eyes and ocular surface disease, reduction in ocular vascular injection (redness), enhancement of corneal clarity, structural integrity and/or refractive ability, and/or inhibition of steroid-induced rise in intraocular pressure when administered topically to the eye. In some embodiments, the composition comprises calcitriol and difluprednate.
PCT/US2011/066036 2010-12-20 2011-12-20 Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity WO2012088044A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201061425082P 2010-12-20 2010-12-20
US61/425,082 2010-12-20
US201161478028P 2011-04-21 2011-04-21
US61/478,028 2011-04-21

Publications (2)

Publication Number Publication Date
WO2012088044A2 WO2012088044A2 (en) 2012-06-28
WO2012088044A3 true WO2012088044A3 (en) 2012-11-01

Family

ID=46314830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/066036 WO2012088044A2 (en) 2010-12-20 2011-12-20 Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity

Country Status (1)

Country Link
WO (1) WO2012088044A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513117A (en) 2015-03-05 2018-05-24 オークランド ユニサービシズ リミテッドＡｕｃｋｌａｎｄ Ｕｎｉｓｅｒｖｉｃｅｓ Ｌｉｍｉｔｅｄ Ophthalmic composition and method of use thereof
CA3122359A1 (en) * 2018-12-06 2020-06-11 Lipicare Life Sciences Ltd. Vitamin d micro-emulsions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010027188A1 (en) * 1997-06-10 2001-10-04 New Vision Co., Ltd. Composition for prophylaxis and/or treatment of dry eye syndrome comprising vitamin D
US20050192264A1 (en) * 2004-02-04 2005-09-01 Penfold Philip L. Slow release steroid composition
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010027188A1 (en) * 1997-06-10 2001-10-04 New Vision Co., Ltd. Composition for prophylaxis and/or treatment of dry eye syndrome comprising vitamin D
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050192264A1 (en) * 2004-02-04 2005-09-01 Penfold Philip L. Slow release steroid composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMITH, S. ET AL.: "Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery", CLIN. OPHTHALMOL., vol. 4, no. 983-89, 7 September 2010 (2010-09-07) *

Also Published As

Publication number Publication date
WO2012088044A2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
US10912765B2 (en) Compositions and methods for non-surgical treatment of ptosis
AU2017329772B2 (en) Pharmaceutical compositions for use in the therapy of blepharitis
WO2009077736A3 (en) A medicament comprising a parasympathetic agonist and a sympathetic antagonist or a sympathetic agonist
BR112014008789A2 (en) prevention and treatment of eye conditions
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
WO2008011836A3 (en) Ophthalmic solutions
MX2015002239A (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions.
WO2012136969A3 (en) Ophthalmic treatments
WO2013171204A3 (en) Ophthalmological vehicle system
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
WO2012061045A3 (en) Methods and compositions for preserving retinal ganglion cells
WO2009111418A3 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2011151685A8 (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2012088044A3 (en) Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity
WO2013046059A3 (en) Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
WO2010047500A2 (en) Composition for prevention or treatment of eye diseases
El-Awady et al. Evaluation of the role of timolol 0.1% gel in myopic regression after laser in situ keratomileusis
JP2017119669A (en) Ophthalmic composition for improved foreign matter feeling
Sim Cataracts following topical application: case report
Kim Hyaluronic acid
Sousa et al. Triamcinolone Intravitreal Injection Results in Previously Vitrectomized Eyes: Longer Effect than We Expected?
CN110870847A (en) Eye drop capable of assisting in treating conjunctivitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11849930

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11849930

Country of ref document: EP

Kind code of ref document: A2